Setileuton
Alternative Names: MK-0633Latest Information Update: 05 Nov 2023
Price :
$50 *
At a glance
- Originator Merck & Co
- Class Antiasthmatics; Benzopyrans; Oxadiazoles
- Mechanism of Action 5-lipoxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Asthma; Atherosclerosis; Chronic obstructive pulmonary disease
Most Recent Events
- 09 Jan 2009 Suspended - Phase-II for Atherosclerosis in USA (PO)
- 31 Jul 2008 Phase-I clinical trials in Asthma in Japan (PO)
- 30 Apr 2008 Phase-I clinical trials in Asthma in USA (PO)